Why Shares of Kymera Therapeutics Jumped on Tuesday

[cafead]

via Kymera is a clinical-stage biotech company that focuses on small molecule protein degrader medicines. After the markets closed on Monday, the company released a presentation that said, among other things, that the company expects to have one or more Investigational New Drug applications (IND) for at least one therapy every year.

article source